{"id":"W2739116172","doi":"10.1200/jco.2017.35.15_suppl.9506","title":"COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i> V600–mutant (mut) melanoma brain metastases (MBM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dabrafenib; Medicine; Trametinib; Cohort; Internal medicine; Asymptomatic; Metastatic melanoma; Melanoma; Oncology; Phases of clinical research; Regimen; Gastroenterology; Clinical trial; Cancer; Vemurafenib; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001071364,0.00119648,0.001740575,0.0003504136,0.0002851996,0.001037481,0.001008537,0.0009915073,0.004343753],"category_scores_gemma":[0.0008274876,0.0005647019,0.0008308324,0.0003468547,0.0005845972,0.0008378769,0.0003177362,0.002724168,0.001248464],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008233449,"about_ca_system_score_gemma":0.001402748,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001129395,"about_ca_topic_score_gemma":0.003576171,"domain_scores_codex":[0.9997733,0.00009635579,0.00001356524,0.00004382848,0.00003081934,0.00004200758],"domain_scores_gemma":[0.9995255,0.00007183187,0.00008978633,0.00003105274,0.00003642474,0.0002453043],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.688028,0.08518849,0.007564514,0.002218211,0.002301185,0.0004588543,0.0004766264,0.002763356,0.04788402,0.0005074285,0.01067302,0.1519362],"study_design_scores_gemma":[0.7205701,0.2586437,0.01046416,0.00005136296,0.000599697,0.0004876493,0.00007479977,0.001882654,0.002325298,0.0001570959,0.004701235,0.00004229634],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874063,0.003705414,0.0006876558,0.000592718,0.0001810425,0.002654334,0.001634514,0.0001709986,0.002967115],"genre_scores_gemma":[0.9854984,0.002890705,0.001776042,0.0008865941,0.0001836229,0.002514091,0.002818939,0.0000442187,0.003387332],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004343753,"threshold_uncertainty_score":0.01453131,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07614107715406832,"score_gpt":0.4387251507223836,"score_spread":0.3625840735683152,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}